Is EQRx an Existential Threat to the Biopharma Industry?

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

One-and-Done Gene Editing: A Feature or Flaw?
EQRx, Exscientia Team Up to Accelerate R&D for Lower-Priced, Better Drugs
Learning from Mistakes in a Pandemic, Aspiring to Make Better Decisions Each Day
Diversity in Clinical Trials is in Everyone’s Interest